Rhythm Pharmaceuticals (RYTM) EBIT (2020 - 2025)
Historic EBIT for Rhythm Pharmaceuticals (RYTM) over the last 6 years, with Q3 2025 value amounting to -$52.7 million.
- Rhythm Pharmaceuticals' EBIT fell 1997.95% to -$52.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$186.2 million, marking a year-over-year increase of 2986.91%. This contributed to the annual value of -$265.5 million for FY2024, which is 4401.57% down from last year.
- Latest data reveals that Rhythm Pharmaceuticals reported EBIT of -$52.7 million as of Q3 2025, which was down 1997.95% from -$45.3 million recorded in Q2 2025.
- Over the past 5 years, Rhythm Pharmaceuticals' EBIT peaked at -$34.4 million during Q1 2021, and registered a low of -$139.9 million during Q1 2024.
- Moreover, its 5-year median value for EBIT was -$44.2 million (2021), whereas its average is -$49.7 million.
- Its EBIT has fluctuated over the past 5 years, first plummeted by 16629.42% in 2024, then soared by 6639.86% in 2025.
- Over the past 5 years, Rhythm Pharmaceuticals' EBIT (Quarter) stood at -$51.0 million in 2021, then rose by 17.43% to -$42.1 million in 2022, then grew by 1.99% to -$41.3 million in 2023, then rose by 0.02% to -$41.3 million in 2024, then decreased by 27.63% to -$52.7 million in 2025.
- Its EBIT was -$52.7 million in Q3 2025, compared to -$45.3 million in Q2 2025 and -$47.0 million in Q1 2025.